Abstract:To the Editor: In former times, traditional Chinese medicine (TCM) individualized its treatment protocol or clinical practice without considering the principles of modern medicine. The standard methodology of random selection, blinding and placebo control, followed by statistical analysis was generally overlooked. This had a negative effect on the development of TCM. Recently, the volume of applied research in Chinese medicine is growing rapidly and the quality is improving.1 There is good evidence supporting the use of some Chinese patent medicine treatments.2–4 Further, there is a more open attitude to Chinese medicine among conventional health professionals, partly explained by the rise of evidence-based medicine (EBM). Changes are occurring in the clinical research of TCM. Firstly, researchers are starting to emphasize the importance of clinical trials.5 Many experts including clinicians, pharmacologists, statisticians and epidemiologists are discussing and formulating clinical trial protocols for TCM. Secondly, quality control is being emphasized for the process of trials more than before.6 Thirdly, clinical researchers and journal editors are moving to accept CONSORT for TCM with the help of the support of EBM experts.7 Lastly, some experts of TCM are exploring evaluation methods suitable for TCM.8 While modern medicine has a well established system of clinical research applying evidence-based methods, traditional Chinese medicine has not developed its own system of research, despite its long history. We suggest the introduction of a new pattern named as ‘Three Steps’ in clinical research of TCM. The first is secondary study of literature; the second is original study; and the third is a methodology study. After a clinical theme is defined, a researcher should search the medical literature to identify all relevant studies. According to the standard approach of EBM, the researcher should appraise the literature firstly and decide whether there is meaningful evidence. If the answer is reliable, evidence from the studies can be combined by means of meta-analysis. If there is no or insufficient evidence, the second step is to design and conduct a suitable study using high quality methods. On the basis of this second step, it is possible that some new methodology might emerge. Randomized controlled trials have already been conducted in TCM. However, with the emerging of Circular Model,9 people begin to scan the hierarchy model again which emphasizes internal validity and experimental evidence. The circle method has no preferred orientation with the contrast of the hierarchy method. It might be a more fitting image for clinical research by balancing the weaknesses of one method with the strengths of another. Chinese medicine is indeed different from western medicine, while TCM is an individual therapeutic method for diseases or conditions. The basic principles for evaluation are similar to western medicine although the special features in TCM should be highlighted. We also should consider the current possibilities for reporting the details of TCM studies. There should be a balance between what is ideal and what is feasible. If the aim of a clinical trail is to evaluate the efficacy of treatment of a disease or symptom with TCM, the inclusion criteria should be internationally or nationally recognized and the criteria should be included. If the aim of a particular Chinese medicine is only to treat specific TCM symptoms it is important to report the TCM diagnostic criteria and this should also be related to the aim of the treatment. If the aim is to treat a disease or symptom, outcome measures should be patient related and internationally or nationally recognized. If the aim of a Chinese medicine is only to improve specific TCM symptom, it is necessary to report TCM outcome measures. The best evidence which should be systematically evaluated, reviewed, summarized, and disseminated should lead to evidence based decision making instead of experience based decision making in traditional Chinese medicine.

Expert Consensus on Key Issues of Quality Control in Clinical Trials of New Drugs of Traditional Chinese Medicine

[Development of clinical trial of new drugs of traditional Chinese medicines]

Development and changes of quality control of clinical trials in China

Construction of quality management system with Chinese characteristic for drug clinical trial institution

Qualities of Controlled Clinical Trials Relevant to Acupuncture and Moxibustion Treatment of Cardiovascular Disease in Literatures Published in China from 1990——2009

Improving the Quality of Randomized Controlled Trials in Chinese Herbal Medicine, Part III: Quality Control of Chinese Herbal Medicine Used in Randomized Controlled Trials.

Investigation of Problems in Clinical Drug Trials in the Past 5 years

Quality Problems of Clinical Trials in China: Evidence from Quality Related Studies

New Trends for Clinical Research of Traditional Chinese Medicine in China

Administration and quality control of large-scale clinical trials of traditional Chinese medicine]

Current Status of Clinical Trials on Drugs and GCP in China

Clinical Trials of Traditional Chinese Medicine in China: Status and Evaluation

Clinical Research Report on Traditional Chinese patent medicines and Traditional Chinese Classic Famous Prescriptions (2022)

Overview of the quality standard research of traditional Chinese medicine

Quality assessment of reporting of randomization, allocation concealment, and blinding in traditional chinese medicine RCTs: A review of 3159 RCTs identified from 260 systematic reviews

Quality assessment of clinical trial registration with traditional Chinese medicine in WHO registries

Clinical Studies with Traditional Chinese Medicine in the Past Decade and Future Research and Development

Perspectives of international multi-center clinical trials on traditional Chinese herbal medicine

Quality Control System of Drug Clinical Trial Institution

The Quality of Reporting of Randomized Controlled Trials of Traditional Chinese Medicine: a Survey of 13 Randomly Selected Journals from Mainland China.

[Consensus on Collaborative Ethical Review of Multi-Center Clinical Trials of New Drugs of Traditional Chinese Medicine (version 1.0)].